Stroke Patients Benefit from Using AI
Trial results demonstrated that stroke survivors were more likely to take an anti-blood clot treatment when using an artificial intelligence (AI) platform.
Trial results demonstrated that stroke survivors were more likely to take an anti-blood clot treatment when using an artificial intelligence (AI) platform than patients who received treatment normally. The AI platform used software algorithms on smartphones to confirm patient identity, medication and medication ingestion.
Read the full release
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Related Articles
Everything to Know About FDA’s Push Towards Radical Transparency in 2025September 17th 2025
IQVIA and Veeva Join Forces to Improve Efficiency and Patient OutcomesSeptember 17th 2025
Managing Background Therapies in the NIMBLE Phase III TrialSeptember 17th 2025
Generative AI Transforms Clinical Study Report DevelopmentSeptember 16th 2025
.png "BioPharm International")
.png "Pharmaceutical Commerce"){kind=logo}
.png "Turbo Machinery Magazine")
.png){kind=spacer}
